Gene: PRKN

5071
AR-JP|LPRS2|PARK2|PDJ
parkin RBR E3 ubiquitin protein ligase
protein-coding
6q26
Ensembl:ENSG00000185345 MIM:602544 Vega:OTTHUMG00000015970 UniprotKB:O60260
NG_008289.2
SNP Mapped
2   ANCO-SNPs
ND
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.633e-1 (AD)  8.070e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs4709595chr6:162308349 (GRCh38.p7)G>Tnicotine dependenceSNV(Single Nucleotide Variation)
rs16892573chr6:161475487 (GRCh38.p7)G>A / G>Cnicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
D0140131,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt"1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Ketoconazole results in increased expression of PRKN mRNA]"25787151
D0140131,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt"1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Ketoconazole results in increased expression of PRKN protein]"25787151
D000082Acetaminophen[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of PRKN mRNA25607892
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of PRKN gene27153756
D000643Ammonium ChlorideAmmonium Chloride affects the expression of PRKN mRNA16483693
D000726Androgen Antagonists[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of PRKN mRNA25607892
D000968Antimycin A[Oligomycins co-treated with Antimycin A] affects the localization of PRKN protein28673964
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of PRKN mRNA24449571
D001151ArsenicArsenic affects the methylation of PRKN gene25304211
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of PRKN mRNA21774909
C072553benzyloxycarbonylleucyl-leucyl-leucine aldehydebenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [PRKN protein results in decreased expression of SLC11A2 protein alternative form]20089134
C072553benzyloxycarbonylleucyl-leucyl-leucine aldehydebenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein]28673964
C072553benzyloxycarbonylleucyl-leucyl-leucine aldehydebenzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of PRKN mRNA18586549
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of PRKN mRNA25607892
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of PRKN mRNA25607892
C006780bisphenol Abisphenol A results in decreased expression of PRKN mRNA25181051
C006780bisphenol Abisphenol A results in increased expression of and affects the localization of PRKN protein26139607
C006780bisphenol Abisphenol A results in increased expression of PRKN mRNA26139607
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of PRKN mRNA25607892
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of PRKN mRNA25607892
D002251Carbon TetrachlorideCarbon Tetrachloride results in decreased expression of PRKN protein26882442
D002251Carbon TetrachlorideMelatonin inhibits the reaction [Carbon Tetrachloride results in decreased expression of PRKN protein]26882442
D002258Carbonyl Cyanide m-Chlorophenyl HydrazoneBECN1 protein inhibits the reaction [BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]]24879156
D002258Carbonyl Cyanide m-Chlorophenyl HydrazoneCarbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein22872702|2607038
D002258Carbonyl Cyanide m-Chlorophenyl Hydrazone[Carbonyl Cyanide m-Chlorophenyl Hydrazone co-treated with PRKN protein] results in increased expression of PINK1 protein28673964
D002258Carbonyl Cyanide m-Chlorophenyl HydrazoneCarbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [AMBRA1 protein binds to PRKN protein]24879156
D002258Carbonyl Cyanide m-Chlorophenyl HydrazoneCarbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein]24879156
D002258Carbonyl Cyanide m-Chlorophenyl HydrazoneCarbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [PIK3C3 protein binds to PRKN protein]24879156
D002258Carbonyl Cyanide m-Chlorophenyl HydrazoneBECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]24879156
D002258Carbonyl Cyanide m-Chlorophenyl HydrazoneBECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased phosphorylation of PRKN protein]24879156
D002258Carbonyl Cyanide m-Chlorophenyl HydrazoneCarbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein24879156
D002258Carbonyl Cyanide m-Chlorophenyl HydrazoneCarbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein]24879156
D002258Carbonyl Cyanide m-Chlorophenyl HydrazoneCarbonyl Cyanide m-Chlorophenyl Hydrazone results in increased phosphorylation of PRKN protein24879156
D002258Carbonyl Cyanide m-Chlorophenyl HydrazonePINK1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]24879156
D002518Ceramidesepoxomicin inhibits the reaction [PRKN protein results in decreased susceptibility to Ceramides]12588799
D002518CeramidesPRKN protein inhibits the reaction [Ceramides affects the localization of CYCS protein]12588799
D002518CeramidesPRKN protein inhibits the reaction [Ceramides results in increased activity of CASP3 protein]12588799
D002518CeramidesPRKN protein results in decreased susceptibility to Ceramides12588799
D020111Chlorodiphenyl (54% Chlorine)Chlorodiphenyl (54% Chlorine) results in increased expression of PRKN protein16174552
D004390ChlorpyrifosChlorpyrifos affects the localization of PRKN protein26070385
D004390ChlorpyrifosPRKN protein inhibits the reaction [Chlorpyrifos results in decreased expression of NDUFS3 protein]26070385
D004390ChlorpyrifosPRKN protein inhibits the reaction [Chlorpyrifos results in increased cleavage of CASP3 protein]26070385
D004390ChlorpyrifosPRKN protein inhibits the reaction [Chlorpyrifos results in increased expression of CASP3 protein modified form]26070385
D003474CurcuminCurcumin inhibits the reaction [Cisplatin results in increased expression of PRKN protein]28698153
D013759DronabinolDronabinol affects the reaction [PRKN mutant form affects the activity of TH protein]15882845
D003976DiazinonDiazinon results in decreased expression of PRKN mRNA21968025
D003993Dibutyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of PRKN mRNA25607892
D002945CisplatinCisplatin results in increased expression of PRKN protein28698153
D002945CisplatinCurcumin inhibits the reaction [Cisplatin results in increased expression of PRKN protein]28698153
D003633Dichlorodiphenyl Dichloroethylene[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of PRKN mRNA25607892
D004051Diethylhexyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of PRKN mRNA25607892
D007980LevodopaLevodopa inhibits the reaction [Oxidopamine results in increased expression of PRKN mRNA]25129099
D004298DopamineDopamine results in increased expression of PRKN mRNA16987221
D004298DopaminePRKN protein inhibits the reaction [Dopamine results in increased abundance of Reactive Oxygen Species]15198987
D004298DopaminePRKN protein inhibits the reaction [Dopamine results in increased cleavage of CASP3 protein]15198987
D004298DopaminePRKN protein inhibits the reaction [Dopamine results in increased cleavage of PARP1 protein]15198987
D004298DopaminePRKN protein inhibits the reaction [Dopamine results in increased phosphorylation of JUN protein]15198987
D004317DoxorubicinDoxorubicin results in increased expression of PRKN protein26678157
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of PRKN mRNA25607892
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of PRKN mRNA25607892
C109476epoxiconazole[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of PRKN mRNA25607892
C078846epoxomicinepoxomicin results in decreased expression of PRKN mRNA18586549
C078846epoxomicinepoxomicin inhibits the reaction [PRKN protein results in decreased susceptibility to Ceramides]12588799
C078846epoxomicinepoxomicin results in decreased expression of PRKN mRNA18586549
D005038EthylnitrosoureaEthylnitrosourea results in increased mutagenesis of PRKN exon17156454
C069837fullerene C60fullerene C60 results in decreased expression of PRKN mRNA19167457
C039281furanfuran results in increased methylation of PRKN gene22079235
D006861Hydrogen PeroxideHydrogen Peroxide results in increased expression of PRKN mRNA25787151
D006861Hydrogen PeroxideHydrogen Peroxide results in increased expression of PRKN protein25787151
C016517indole-3-carbinolindole-3-carbinol affects the expression of PRKN mRNA21396975
C016527isoquercitrinisoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PRKN mRNA]25129099
C561695(+)-JQ1 compound(+)-JQ1 compound results in increased expression of PRKN mRNA24796395
D007654Ketoconazole"1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Ketoconazole results in increased expression of PRKN mRNA]"25787151
D007654Ketoconazole"1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Ketoconazole results in increased expression of PRKN protein]"25787151
D007654KetoconazoleKetoconazole results in increased expression of PRKN mRNA25787151
D007654KetoconazoleKetoconazole results in increased expression of PRKN protein25787151
D007654KetoconazolePRKN protein results in increased susceptibility to Ketoconazole25787151
D007654Ketoconazoletempol inhibits the reaction [Ketoconazole results in increased expression of PRKN mRNA]25787151
D007654Ketoconazoletempol inhibits the reaction [Ketoconazole results in increased expression of PRKN protein]25787151
C002385linsidominelinsidomine results in increased expression of PRKN protein12880480
C002385linsidomineSelegiline inhibits the reaction [linsidomine results in increased expression of PRKN protein]12880480
D008044Linuron[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of PRKN mRNA25607892
D008345ManganesePRKN gene mutant form affects the susceptibility to Manganese22841634
D008345ManganesePRKN protein results in decreased transport of Manganese20089134
D008345ManganeseManganese results in decreased expression of PRKN mRNA19781568
D008345ManganeseManganese results in increased expression of PRKN protein20798247
C025340manganese chloridemanganese chloride results in decreased expression of PRKN mRNA27913844
C025340manganese chloridemanganese chloride results in increased methylation of PRKN gene27913844
C025340manganese chloridemanganese chloride results in decreased expression of PRKN mRNA20635692
C025340manganese chloridemanganese chloride results in increased expression of PRKN protein20798247
D008550MelatoninMelatonin inhibits the reaction [Carbon Tetrachloride results in decreased expression of PRKN protein]26882442
D008694MethamphetamineMethamphetamine results in decreased expression of PRKN protein28661099
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium results in increased expression of PRKN mRNA16987221
D0156321-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine"PRKN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH]"25447324
D0156321-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine"PRKN mutant form results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine"25447324
D0156321-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine"PRKN protein results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine"22043175
D008825MiconazoleMiconazole results in increased expression of PRKN mRNA22262564
C555916MitoTEMPOMitoTEMPO inhibits the reaction [trifloxystrobin results in increased expression of PRKN protein]27853101
D009538NicotineNicotine results in decreased expression of PRKN mRNA16949557
D026422S-NitrosoglutathioneS-Nitrosoglutathione inhibits the reaction [PRKN protein binds to TP53 promoter]23985028
D026422S-NitrosoglutathioneS-Nitrosoglutathione inhibits the reaction [PRKN protein results in decreased expression of TP53 mRNA]23985028
D026422S-NitrosoglutathioneS-Nitrosoglutathione inhibits the reaction [PRKN protein results in decreased expression of TP53 protein]23985028
D026422S-NitrosoglutathioneS-Nitrosoglutathione results in increased nitrosation of and affects the localization of PRKN protein23985028
D026422S-Nitrosoglutathione[S-Nitrosoglutathione results in increased nitrosation of PRKN protein] inhibits the reaction [PRKN protein binds to TP53 promoter]23985028
D026422S-Nitrosoglutathione[S-Nitrosoglutathione results in increased nitrosation of PRKN protein] inhibits the reaction [PRKN protein results in decreased expression of TP53 mRNA]23985028
D026422S-Nitrosoglutathione[S-Nitrosoglutathione results in increased nitrosation of PRKN protein] inhibits the reaction [PRKN protein results in decreased expression of TP53 protein]23985028
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of PRKN mRNA25607892
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of PRKN mRNA25607892
D016627OxidopaminePRKN protein inhibits the reaction Oxidopamine15198987
D016627Oxidopamineisoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PRKN mRNA]25129099
D016627OxidopamineLevodopa inhibits the reaction [Oxidopamine results in increased expression of PRKN mRNA]25129099
D016627OxidopamineOxidopamine results in increased expression of PRKN mRNA25129099
D016627OxidopamineRutin inhibits the reaction [Oxidopamine results in increased expression of PRKN mRNA]25129099
D009840Oligomycins[Oligomycins co-treated with Antimycin A] affects the localization of PRKN protein28673964
D010269ParaquatPRKN protein results in decreased susceptibility to Paraquat22043175
C045362prochloraz[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of PRKN mRNA25607892
C035988procymidone[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of PRKN mRNA25607892
D011441PropylthiouracilPropylthiouracil results in increased expression of PRKN mRNA24780913
D017382Reactive Oxygen SpeciesPRKN protein inhibits the reaction [Dopamine results in increased abundance of Reactive Oxygen Species]15198987
D017382Reactive Oxygen SpeciesPRKN protein results in decreased abundance of Reactive Oxygen Species15198987
C059514resveratrolPRKN gene mutant form affects the reaction [resveratrol results in increased expression of COX1 mRNA]24582596
C059514resveratrolPRKN gene mutant form inhibits the reaction [resveratrol results in increased expression of CAT mRNA]24582596
C059514resveratrolPRKN gene mutant form inhibits the reaction [resveratrol results in increased expression of SOD2 mRNA]24582596
C059514resveratrolPRKN gene mutant form promotes the reaction [resveratrol results in increased expression of CYCS mRNA]24582596
C059514resveratrolresveratrol affects the reaction [PRKN gene mutant form affects the expression of PPARGC1A mRNA]24582596
C059514resveratrolresveratrol affects the reaction [PRKN gene mutant form affects the expression of PPARGC1A protein]24582596
C089032rimonabantrimonabant affects the reaction [PRKN mutant form affects the activity of TH protein]15882845
D012402RotenonePRKN gene mutant form results in increased susceptibility to Rotenone17687034
D012402RotenonePRKN protein affects the susceptibility to Rotenone20940149
D012402RotenonePRKN protein inhibits the reaction [LRRK2 gene polymorphism results in increased susceptibility to Rotenone]19741132
D012402RotenonePRKN protein results in decreased susceptibility to Rotenone17687034|1974113
D012431RutinRutin inhibits the reaction [Oxidopamine results in increased expression of PRKN mRNA]25129099
D012642SelegilineSelegiline inhibits the reaction [linsidomine results in increased expression of PRKN protein]12880480
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of PRKN protein27613482
C471405sorafenibbenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein]28673964
C471405sorafenibPINK1 protein affects the reaction [sorafenib affects the localization of PRKN protein]28673964
C471405sorafenibsorafenib affects the localization of PRKN protein28673964
C471405sorafenib[sorafenib co-treated with PRKN protein] results in decreased expression of CASP3 protein28673964
C471405sorafenib[sorafenib co-treated with PRKN protein] results in decreased expression of MCL1 protein28673964
C471405sorafenib[sorafenib co-treated with PRKN protein] results in increased cleavage of PARP1 protein28673964
C471405sorafenib[sorafenib co-treated with PRKN protein] results in increased expression of PINK1 protein28673964
C471405sorafenibsorafenib results in increased ubiquitination of PRKN protein28673964
C001803tempoltempol inhibits the reaction [Ketoconazole results in increased expression of PRKN mRNA]25787151
C001803tempoltempol inhibits the reaction [Ketoconazole results in increased expression of PRKN protein]25787151
D013853ThioacetamideThioacetamide results in decreased expression of PRKN mRNA23411599
C467051trifloxystrobinMitoTEMPO inhibits the reaction [trifloxystrobin results in increased expression of PRKN protein]27853101
C467051trifloxystrobintrifloxystrobin results in increased expression of PRKN protein27853101
D014403TubocurarineTubocurarine results in decreased expression of PRKN mRNA16949557
D014634ValinomycinValinomycin affects the localization of PRKN protein22872702
C025643vinclozolin[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of PRKN mRNA25607892

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000976transcription regulatory region sequence-specific DNA binding-IDA23985028  
GO:0001664G-protein coupled receptor binding-IPI12150907  
GO:0003700DNA-binding transcription factor activity-IC23985028  
GO:0003779actin binding-IPI21753002  
GO:0004842ubiquitin-protein transferase activity-IDA11078524  15728840  17097639  18541373  20889974  21376232  
24784582  24896179  
GO:0004842ubiquitin-protein transferase activity-TAS-  
GO:0005515protein binding-IPI10888878  11078524  11439185  11590439  12364339  12628165  
12925569  14532270  15603737  15728840  15987638  16096643  
16189514  16332688  16352719  17097639  19060904  19146857  
19229105  19725078  19966284  20153330  20889486  20889974  
21376232  21753002  22078885  22082830  23453807  23620051  
23858059  23933751  24063750  24270810  24357652  24660806  
25244949  
GO:0008013beta-catenin binding-IDA19591802  
GO:0008270zinc ion binding-TAS23626584  
GO:0015631tubulin binding-IPI21753002  
GO:0017124SH3 domain binding-TAS23626584  
GO:0019899enzyme binding-IPI19725078  
GO:0019900kinase binding-IPI17512523  19229105  19880420  24187134  
GO:0019901protein kinase binding-IPI20798600  
GO:0030165PDZ domain binding-IPI17512523  
GO:0030544Hsp70 protein binding-IPI12150907  21753002  
GO:0031072heat shock protein binding-IPI12150907  
GO:0031624ubiquitin conjugating enzyme binding-IBA21873635  
GO:0031624ubiquitin conjugating enzyme binding-IDA10973942  
GO:0031624ubiquitin conjugating enzyme binding-IPI11439185  12628165  
GO:0031625ubiquitin protein ligase binding-IPI12150907  21532592  23453807  
GO:0042802identical protein binding-IPI21694720  
GO:0042826histone deacetylase binding-IPI21753002  
GO:0043130ubiquitin binding-IDA24784582  
GO:0043274phospholipase binding-IPI19725078  
GO:0051087chaperone binding-IPI15603737  19725078  21753002  
GO:0061630ubiquitin protein ligase activity-IBA21873635  
GO:0061630ubiquitin protein ligase activity-IDA10973942  11439185  12150907  12628165  12925569  16227987  
19229105  19880420  20823226  21376232  23858059  25621951  
GO:0061630ubiquitin protein ligase activity-NAS10973942  18221368  
GO:0061630ubiquitin protein ligase activity-TAS-  
GO:0097602cullin family protein binding-IDA12628165  
GO:1990381ubiquitin-specific protease binding-IPI24063750  
GO:1990444F-box domain binding-IPI12628165  
GO ID GO Term Qualifier Evidence PubMed
GO:0000122negative regulation of transcription by RNA polymerase II-IMP23985028  
GO:0000209protein polyubiquitination-IBA21873635  
GO:0000209protein polyubiquitination-IDA12150907  16227987  18541373  19880420  
GO:0000266mitochondrial fission-ISS-  
GO:0000422autophagy of mitochondrion-IBA21873635  
GO:0000422autophagy of mitochondrion-IDA25621951  
GO:0000422autophagy of mitochondrion-IMP19029340  23933751  24896179  
GO:0000423mitophagy-IEA-  
GO:0001933negative regulation of protein phosphorylation-IBA21873635  
GO:0001933negative regulation of protein phosphorylation-IDA17512523  
GO:0001964startle response-IEA-  
GO:0006351transcription, DNA-templated-IEA-  
GO:0006511ubiquitin-dependent protein catabolic process-IC21376232  
GO:0006511ubiquitin-dependent protein catabolic process-IDA12925569  17097639  
GO:0006511ubiquitin-dependent protein catabolic process-NAS12628165  
GO:0006511ubiquitin-dependent protein catabolic process-TAS10888878  
GO:0006513protein monoubiquitination-IDA20889974  
GO:0006513protein monoubiquitination-IMP24660806  
GO:0006979response to oxidative stress-ISS-  
GO:0007005mitochondrion organization-ISS-  
GO:0007417central nervous system development-TAS9560156  
GO:0007612learning-IEA-  
GO:0008344adult locomotory behavior-ISS-  
GO:0010498proteasomal protein catabolic process-IMP19725078  
GO:0010506regulation of autophagy-IDA20889974  
GO:0010628positive regulation of gene expression-IMP19725078  
GO:0010629negative regulation of gene expression-IMP19725078  22314364  
GO:0010636positive regulation of mitochondrial fusion-IMP23453807  
GO:0010637negative regulation of mitochondrial fusion-ISS-  
GO:0010821regulation of mitochondrion organization-IBA21873635  
GO:0010821regulation of mitochondrion organization-IDA21113145  
GO:0010821regulation of mitochondrion organization-IGI19279012  
GO:0010821regulation of mitochondrion organization-NAS20890124  
GO:0010906regulation of glucose metabolic process-TAS23626584  
GO:0010994free ubiquitin chain polymerization-IMP24660806  
GO:0014059regulation of dopamine secretion-TAS21563316  
GO:0016236macroautophagy-TAS-  
GO:0016567protein ubiquitination-IDA10973942  11439185  12628165  17314283  
GO:0016567protein ubiquitination-IMP23933751  26911690  
GO:0016579protein deubiquitination-TAS-  
GO:0031396regulation of protein ubiquitination-IGI23212910  
GO:0031396regulation of protein ubiquitination-IMP20871098  
GO:0031647regulation of protein stability-IMP26911690  
GO:0031648protein destabilization-IDA19591802  
GO:0032092positive regulation of protein binding-IMP26911690  
GO:0032232negative regulation of actin filament bundle assembly-IDA17512523  
GO:0032368regulation of lipid transport-TAS23626584  
GO:0032436positive regulation of proteasomal ubiquitin-dependent protein catabolic process-IBA21873635  
GO:0032436positive regulation of proteasomal ubiquitin-dependent protein catabolic process-TAS24115276  
GO:0033132negative regulation of glucokinase activity-IDA24187134  
GO:0034620cellular response to unfolded protein-TAS18221368  
GO:0034976response to endoplasmic reticulum stress-IMP21113145  
GO:0035249synaptic transmission, glutamatergic-IEA-  
GO:0035519protein K29-linked ubiquitination-TAS23626584  
GO:0036503ERAD pathway-NAS10973942  
GO:0042053regulation of dopamine metabolic process-IMP22314364  
GO:0042415norepinephrine metabolic process-IEA-  
GO:0042417dopamine metabolic process-TAS23626584  
GO:0042981regulation of apoptotic process-IBA21873635  
GO:0043123positive regulation of I-kappaB kinase/NF-kappaB signaling-IDA17314283  19880420  
GO:0043123positive regulation of I-kappaB kinase/NF-kappaB signaling-IMP23453807  
GO:0043161proteasome-mediated ubiquitin-dependent protein catabolic process-IDA11439185  21376232  
GO:0043388positive regulation of DNA binding-IDA17314283  
GO:0043524negative regulation of neuron apoptotic process-IDA12628165  22511790  23985028  
GO:0044257cellular protein catabolic process-IMP21376232  
GO:0044267cellular protein metabolic process-TAS-  
GO:0044314protein K27-linked ubiquitination-TAS20098416  23626584  
GO:0044828negative regulation by host of viral genome replication-IDA25244949  
GO:0045732positive regulation of protein catabolic process-TAS22988876  
GO:0045944positive regulation of transcription by RNA polymerase II-IDA23453807  
GO:0046329negative regulation of JNK cascade-ISS-  
GO:0046676negative regulation of insulin secretion-IDA24187134  
GO:0050821protein stabilization-IMP19229105  
GO:0051582positive regulation of neurotransmitter uptake-IMP22314364  
GO:0051583dopamine uptake involved in synaptic transmission-IEA-  
GO:0051865protein autoubiquitination-IDA12628165  15728840  16352719  17512523  
GO:0051881regulation of mitochondrial membrane potential-IEA-  
GO:0055069zinc ion homeostasis-ISS-  
GO:0060548negative regulation of cell death-IDA15603737  
GO:0060828regulation of canonical Wnt signaling pathway-TAS24115276  
GO:0061734parkin-mediated stimulation of mitophagy in response to mitochondrial depolarization-IDA19029340  
GO:0070050neuron cellular homeostasis-ISS-  
GO:0070534protein K63-linked ubiquitination-IDA15728840  17314283  19880420  25621951  
GO:0070534protein K63-linked ubiquitination-NAS20890124  
GO:0070534protein K63-linked ubiquitination-TAS18221368  
GO:0070585protein localization to mitochondrion-IEA-  
GO:0070842aggresome assembly-IMP14645198  
GO:0070936protein K48-linked ubiquitination-IDA21376232  23858059  
GO:0070979protein K11-linked ubiquitination-IDA25621951  
GO:0071287cellular response to manganese ion-TAS23628791  
GO:0085020protein K6-linked ubiquitination-IDA25621951  
GO:0085020protein K6-linked ubiquitination-TAS23626584  
GO:0090090negative regulation of canonical Wnt signaling pathway-IDA19591802  
GO:0090090negative regulation of canonical Wnt signaling pathway-TAS22988876  
GO:0090141positive regulation of mitochondrial fission-ISS-  
GO:0090201negative regulation of release of cytochrome c from mitochondria-IDA19880420  23453807  
GO:0097237cellular response to toxic substance-IMP12628165  
GO:0098779positive regulation of mitophagy in response to mitochondrial depolarization-IDA20457763  
GO:0098779positive regulation of mitophagy in response to mitochondrial depolarization-IMP20871098  23212910  
GO:0099074mitochondrion to lysosome transport-IDA24446486  
GO:1900407regulation of cellular response to oxidative stress-IBA21873635  
GO:1900407regulation of cellular response to oxidative stress-IDA24446486  
GO:1900407regulation of cellular response to oxidative stress-IMP22314364  
GO:1900407regulation of cellular response to oxidative stress-ISS-  
GO:1901215negative regulation of neuron death-IGI21376232  
GO:1901800positive regulation of proteasomal protein catabolic process-IGI23858059  
GO:1902236negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway-IDA11439185  12150907  23453807  
GO:1902236negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway-IMP10973942  21113145  
GO:1902254negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator-IMP23985028  
GO:1902283negative regulation of primary amine oxidase activity-IMP22314364  
GO:1902530positive regulation of protein linear polyubiquitination-IGI23453807  
GO:1902803regulation of synaptic vesicle transport-NAS21563316  
GO:1903202negative regulation of oxidative stress-induced cell death-NAS24522549  
GO:1903202negative regulation of oxidative stress-induced cell death-TAS24252804  
GO:1903214regulation of protein targeting to mitochondrion-NAS20890124  
GO:1903265positive regulation of tumor necrosis factor-mediated signaling pathway-IDA23453807  
GO:1903351cellular response to dopamine-TAS23626584  
GO:1903377negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway-IDA17314283  
GO:1903382negative regulation of endoplasmic reticulum stress-induced neuron intrinsic apoptotic signaling pathway-IEA-  
GO:1903542negative regulation of exosomal secretion-IMP26911690  
GO:1903599positive regulation of autophagy of mitochondrion-IDA26310625  
GO:1903861positive regulation of dendrite extension-IEA-  
GO:1904049negative regulation of spontaneous neurotransmitter secretion-IMP22314364  
GO:1905281positive regulation of retrograde transport, endosome to Golgi-NAS26911690  
GO:1905366negative regulation of intralumenal vesicle formation-IMP26911690  
GO:1905477positive regulation of protein localization to membrane-IC26911690  
GO:1905477positive regulation of protein localization to membrane-IMP26911690  
GO:2000377regulation of reactive oxygen species metabolic process-IMP18541373  
GO:2000378negative regulation of reactive oxygen species metabolic process-IGI18541373  
GO ID GO Term Qualifier Evidence PubMed
GO:0000151ubiquitin ligase complex-IBA21873635  
GO:0000151ubiquitin ligase complex-IDA12150907  17314283  23933751  
GO:0005634nucleus-IDA23985028  
GO:0005737cytoplasm-IBA21873635  
GO:0005737cytoplasm-IDA17512523  19591802  21376232  23858059  23985028  25244949  
GO:0005739mitochondrion-IBA21873635  
GO:0005739mitochondrion-IDA19229105  20889974  23933751  25244949  
GO:0005739mitochondrion-IMP19029340  
GO:0005739mitochondrioncolocalizes_withIMP21508222  
GO:0005783endoplasmic reticulum-IBA21873635  
GO:0005783endoplasmic reticulum-IDA12150907  
GO:0005794Golgi apparatus-IBA21873635  
GO:0005794Golgi apparatus-IDA17097639  
GO:0005829cytosol-IBA21873635  
GO:0005829cytosol-IDA19029340  19229105  19880420  20889974  21753002  23933751  
GO:0005829cytosol-IMP21508222  
GO:0005829cytosol-TAS-  
GO:0016235aggresome-IDA14645198  
GO:0016607nuclear speck-IDA-  
GO:0019005SCF ubiquitin ligase complexNOTIDA12628165  
GO:0043005neuron projection-IDA12925569  
GO:0048471perinuclear region of cytoplasm-IDA17097639  
GO:0071797LUBAC complexcolocalizes_withIPI23453807  
GO:0097413Lewy body-TAS24522549  
GO:0098793presynapse-IEA-  
GO:0099073mitochondrion-derived vesiclecolocalizes_withIDA24446486  
GO:1990452Parkin-FBXW7-Cul1 ubiquitin ligase complex-IPI12628165  
KEGG ID KEGG Term
hsa04120Ubiquitin mediated proteolysis
hsa04141Protein processing in endoplasmic reticulum
hsa05012Parkinson's disease
Reactome ID Reactome Term Evidence
R-HSA-1280218Adaptive Immune SystemTAS
R-HSA-168256Immune SystemTAS
R-HSA-392499Metabolism of proteinsTAS
R-HSA-5205647MitophagyTAS
R-HSA-5205685Pink/Parkin Mediated MitophagyTAS
R-HSA-5688426DeubiquitinationTAS
R-HSA-5689877Josephin domain DUBsTAS
R-HSA-597592Post-translational protein modificationTAS
R-HSA-977225Amyloid fiber formationTAS
R-HSA-983168Antigen processing: Ubiquitination & Proteasome degradationTAS
R-HSA-983169Class I MHC mediated antigen processing & presentationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal